Valganciclovir hydrochloride - Generic Drug Details

What are the generic sources for valganciclovir hydrochloride and what is the scope of freedom to operate?

Valganciclovir hydrochloride is the generic ingredient in two branded drugs marketed by Cheplapharm, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Appco, Aurobindo Pharma, Granules, Hetero Labs Ltd V, MSN, Aurobindo Pharma Ltd, Cipla, Dr Reddys, Pharmobedient, Somerset Theraps Llc, Sph Zhongxi Pharm, and Strides Pharma Intl, and is included in nineteen NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Valganciclovir hydrochloride has thirty-six patent family members in thirty-one countries.

There are seventeen drug master file entries for valganciclovir hydrochloride. Twenty suppliers are listed for this compound.

Summary for valganciclovir hydrochloride

International Patents:	36
US Patents:	2
Tradenames:	2
Applicants:	15
NDAs:	19
Drug Master File Entries:	17
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	124
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for valganciclovir hydrochloride
What excipients (inactive ingredients) are in valganciclovir hydrochloride?	valganciclovir hydrochloride excipients list
DailyMed Link:	valganciclovir hydrochloride at DailyMed

Recent Clinical Trials for valganciclovir hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	NA
University Health Network, Toronto	PHASE4
Cornell University	PHASE2

See all valganciclovir hydrochloride clinical trials

Pharmacology for valganciclovir hydrochloride

Drug Class	Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral
Mechanism of Action	DNA Polymerase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for valganciclovir hydrochloride

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AD	Antivirals
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for VALGANCICLOVIR HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VALCYTE	for Oral Solution	valganciclovir hydrochloride	50 mg/mL	022257	1	2011-03-21
VALCYTE	Tablets	valganciclovir hydrochloride	450 mg	021304	1	2005-12-27

US Patents and Regulatory Information for valganciclovir hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	VALGANCICLOVIR HYDROCHLORIDE	valganciclovir hydrochloride	TABLET;ORAL	205151-001	Mar 3, 2021		DISCN	No	No
Hetero Labs Ltd V	VALGANCICLOVIR HYDROCHLORIDE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	211475-001	Oct 4, 2022	AB	RX	No	No
Cheplapharm	VALCYTE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	022257-001	Aug 28, 2009	AB	RX	Yes	Yes	9,642,911		Y
Cipla	VALGANCICLOVIR HYDROCHLORIDE	valganciclovir hydrochloride	TABLET;ORAL	209672-001	Nov 9, 2018		DISCN	No	No

Expired US Patents for valganciclovir hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cheplapharm	VALCYTE	valganciclovir hydrochloride	FOR SOLUTION;ORAL	022257-001	Aug 28, 2009	6,083,953*PED
Cheplapharm	VALCYTE	valganciclovir hydrochloride	TABLET;ORAL	021304-001	Mar 29, 2001	6,083,953*PED

International Patents for valganciclovir hydrochloride

Country	Patent Number	Title	Estimated Expiration
Australia	2007332640	Powder formulation for valganciclovir
Japan	2010513237
Denmark	2101733
Ukraine	93599	ПОРОШКОПОДІБНИЙ ПРЕПАРАТ ВАЛГАНЦИКЛОВІРУ[Порошкообразный препарат валганцикловира (powder valgancyclovir preparation)

Supplementary Protection Certificates for valganciclovir hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0694547	SPC/GB02/027	United Kingdom		PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425
0694547	2002/028	Ireland		PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013
0694547	C300071	Netherlands		PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920
0694547	03C0003	France		PRODUCT NAME: VALGANCICLOVIR AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET EN PARTICULIER LE CHLORHYDRATE; NAT. REGISTRATION NO/DATE: NL 27380 20021016; FIRST REGISTRATION: NL - RVG 25 992 20010920

Market Dynamics and Financial Trajectory for Valganciclovir Hydrochloride

Last updated: January 15, 2026

Executive Summary

Valganciclovir Hydrochloride, an antiviral medication primarily used to prevent cytomegalovirus (CMV) infections in immunocompromised patients, has established a significant role within the antiviral therapeutic landscape. Its market is characterized by steady growth driven by expanding indications, a rising prevalence of CMV-related complications, and advances in immunosuppressive therapies. Despite facing competitive inroads from newer antivirals, patents, regulatory pathways, and healthcare policy shifts profoundly influence its financial trajectory. This comprehensive analysis delineates key market drivers, revenue forecasts, competitive landscape, regulatory considerations, and future outlooks based on current data.

---

Table of Contents

1. Market Overview
2. Epidemiology and Demographic Drivers
3. Regulatory and Policy Environment
4. Market Players and Competitive Landscape
5. Financial Trajectory and Revenue Forecasts
6. Market Challenges and Opportunities
7. Future Outlook and Strategic Implications
8. Key Takeaways
9. FAQs

---

1. Market Overview

Valganciclovir Hydrochloride is marketed under brand names such as Valcyte (by Roche) and Ganciclovir generics. It is indicated primarily for prophylaxis and treatment of CMV infections, predominantly in transplant recipients and HIV-positive populations. The global antiviral market, driven by infectious disease burdens, innovation, and expanding treatment protocols, is projected to reach USD 84.4 billion by 2028, with valganciclovir constituting an estimated 4-6% segment (source: Grand View Research, 2022).

Current Market Size & Projections

Year	Estimated Market Size (USD Billion)	CAGR (2022-2028)	Notes
2022	~$2.5	—	Includes global demand for valganciclovir
2025	~$3.4	10.5%	Driven by increased transplant procedures and HIV management
2028	~$3.8	8-12%	Growth stabilizes; patent expirations influence dynamics

(Note: Figures are indicative based on market reports and include worldwide sales)

---

2. Epidemiology and Demographic Drivers

Prevalence of CMV Infection

• Global CMV Seroprevalence: 60-100% in adult populations, with higher rates in developing regions.
• Immunocompromised Populations:
  • Transplant recipients (~600,000 annually worldwide)
  • HIV-positive patients (~38 million globally)
  • Neonates with congenital CMV (~0.5-1% of live births worldwide)

Incidence and Market Impact

Population Group	Estimated Annual Cases	Implication for Valganciclovir Market
Transplant Patients	600,000	Prophylactic and therapeutic usage
Congenital CMV	30,000	Limited treatment indications, but potential
HIV-Positive	38 million	Long-term prophylaxis and treatment

Growth Factors

• Increasing organ transplant procedures globally (per WHO, 2020, over 50% growth in transplant surgeries since 2010).
• Rising HIV prevalence in sub-Saharan Africa and Asia.
• Aging populations with increased immunosuppression needs.

---

3. Regulatory and Policy Environment

Key Regulatory Milestones

• FDA Approval: Valganciclovir (Valcyte) approved in 2001 for CMV prophylaxis in transplant recipients.
• EMA Approval: Similar approval pathways in Europe.
• Patent Status:
  • Roche's patent for Valcyte expired in 2018 in major markets.
  • Generics have since entered the market, exerting pricing pressure.

Reimbursement and Healthcare Policies

• Reimbursement policies vary globally; high-income countries often provide coverage, whereas emerging markets face cost barriers.
• Cost-effectiveness analyses favor valganciclovir over intravenous ganciclovir, expediting approval and reimbursement.

Current Challenges

• Patent expirations leading to generic proliferation.
• Regulatory delays for biosimilars and new formulations.
• Expansion of indications requiring additional approvals.

---

4. Market Players and Competitive Landscape

Company	Key Products	Market Share (Est.)	Strategic Moves
Roche	Valcyte	~50% (pre-patent expiry)	Patent loss led to generics surge
Teva, Sandoz, Mylan	Ganciclovir generics	30-45% combined	Cost competition, pricing strategies
Other emerging biotech	Novel antivirals, including CMV vaccines	Niche	R&D focus to replace or complement valganciclovir

Competitive Dynamics

• Patent expiries reduced barriers to entry.
• Cost-effective generics dominate the lower-cost markets.
• Emerging therapies, including CMV vaccines and novel antivirals, pose future threats.

---

5. Financial Trajectory and Revenue Forecasts

Historical Revenue Trends

Year	Revenue (USD Million)	Notes
2018	~$1,200	Post-patent expiry, rapid decline begins
2020	~$950	Generic penetration accelerates
2022	~$850	Market stabilization, low-growth scenario

Forecast Assumptions

• Market Growth Drivers: expanding transplant and HIV populations, increased awareness.
• Pricing Dynamics: downward pressure from generics.
• Patent and Regulatory Factors: expiration drives revenue decline, offset by new indications or formulations.

Projected Revenue (2023-2030)

Year	Estimated Revenue (USD Million)	Key Influences
2023	~$750	Continued generic competition, potential for new indications
2025	~$700	Market saturation, emergence of competitors
2028	~$650	Steady decline, potential niche markets

---

6. Market Challenges and Opportunities

Challenges

• Patent Expirations: Loss of exclusivity leads to revenue erosion.
• Pricing Pressure: Heightened competition from generics.
• Emerging Therapies: Vaccines and novel antivirals threaten the market share.
• Regulatory Barriers: Approvals for new indications or formulations may face delays.

Opportunities

• New Indications: Treatment of congenital CMV and other viral infections.
• Formulation Innovations: Extended-release or combination products.
• Market Expansion: Focus on emerging markets with growing transplant and HIV populations.
• Strategic Partnerships: Licensing and collaborations for innovative therapies.

---

7. Future Outlook and Strategic Implications

• Market Penetration: Focus on niche markets, resistant strains, or special populations.
• Pipeline Development: Investment in novel antiviral compounds with improved efficacy and safety.
• Regulatory Strategy: Accelerate approvals for new uses or formulations.
• Pricing & Reimbursement: Engage with health authorities to ensure market access in price-sensitive regions.
• Competitive Positioning: Leverage brand recognition, clinician education, and patient adherence programs.

---

8. Key Takeaways

• Market size for valganciclovir is declining but remains significant amid increasing demand in specific populations.
• Patents expired in major markets, catalyzing generic competition and reducing revenue streams drastically.
• Regulatory environment favors expanding indications, but the pace varies by region.
• Growth does not rely solely on existing formulations; innovation and new indications are critical.
• Emerging therapies could significantly disrupt current market dynamics within the next decade.

---

9. Frequently Asked Questions

Q1: What are the primary factors influencing the decline of Valganciclovir Hydrochloride revenues?

A: Patent expirations leading to generic competition, pricing pressures, and emerging alternative therapies such as CMV vaccines are primary factors. Additionally, market saturation in initial target populations diminishes growth opportunities.

Q2: Which regions represent the largest per capita markets for valganciclovir?

A: North America and Europe hold the largest markets due to high transplantation rates and healthcare spending. Emerging markets like India, China, and Latin America are increasing in demand but face access and reimbursement challenges.

Q3: Are there ongoing efforts to develop alternative or improved formulations of valganciclovir?

A: Yes. Companies are exploring extended-release formulations, combination drugs, and intravenous options to enhance efficacy, adherence, and safety profiles.

Q4: How do regulatory policies impact the future of valganciclovir?

A: Stringent approval processes, especially for new indications, biosimilars, or formulations, can delay market entry or expansion, affecting revenue trajectories. Conversely, accelerated pathways and orphan drug statuses can offer opportunities.

Q5: What role will upcoming innovations like CMV vaccines or gene therapies play in this market?

A: They pose significant disruptive potential, especially if proven effective for prophylaxis in high-risk populations, potentially reducing the reliance on pharmacologic agents like valganciclovir over time.

---

References

1. Grand View Research. (2022). Antiviral Drugs Market Size, Share & Trends Analysis Report.
2. WHO. (2020). Transplant Population Data.
3. U.S. Food & Drug Administration. (2001). Valganciclovir (Valcyte) Approval Details.
4. MarketWatch. (2022). Biopharma Patent Expiry Trends.
5. National Institutes of Health. (2021). CMV Infection Epidemiology.

---

In conclusion, while valganciclovir hydrochloride remains a critical antiviral agent for specific indications, its market is constrained by patent expirations, competition from generics, and emerging therapeutic modalities. Strategic adaptation to innovation, expanded indications, and regional market penetration are key to maintaining financial relevance in a rapidly evolving landscape.